Most Read Articles
Jairia Dela Cruz, 18 Nov 2020
The small molecule fatty acid synthase inhibitor TVB-2640 boasts a win in addressing the three key drivers of nonalcoholic steatohepatitis (NASH)—namely liver fat, fibrosis, and inflammation—in the phase II FASCINATE-1 trial presented during The Liver Meeting Digital Experience of the American Association for the Study of Liver Diseases (AASLD).

MELD-Na underestimates death risk in ACLF patients

23 Nov 2020
Patients with a higher MELD score are given priority for a liver transplant.

The model for end-stage liver disease with sodium correction (MELD-Na) insufficiently captures 90-day mortality among patients with acute-on-chronic liver failure (ACLF), a new study has found.

Of the 71,894 surveyed participants, 26.4 percent (n=18,979) were found to have ACLF. Excessive alcohol use in the preceding year was the most common precipitating event and was responsible for ACLF in 28.7 percent of the cases. Other common underlying causes were gastrointestinal bleeding and infection. Kidney failure (71.9 percent) and cerebral failure (36.0 percent) were common complications.

The median MELD-Na score was 26 for patients with ACLF, as opposed to only 15 in those without ACLF. Categorizing according to the number of organ failures (1, 2, ≥3), the median MELD-Na scores were 24, 27, and 32 for ACLF grade 1, 2, and 3 patients, respectively.

At 90 days, the mortality rate in the ACLF subgroup was 40.0 percent, while only 21.3 percent of their non-ACLF counterparts died. Mortality also seemed to be linked to ACLF grade, with rates of 30.8 percent, 41.6 percent, and 68.8 percent in patients with ACLF grade 1, 2, and 3, respectively.

The actual 90-day mortality rate was consistently higher than the expected number of deaths estimated using the MELD-Na. For instance, 14.5 percent of ACLF patients had MELD-Na scores from 10–20. Comparing the predicted and actual death rates of these patients, the resulting standardized mortality rate was 6.1.

This meant that patients with these MELD-Na scores were at least six times more likely to die than what would be expected based on MELD-Na alone. Only at scores ≥30 was MELD-Na able to accurately anticipate mortality risk among ACLF patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 18 Nov 2020
The small molecule fatty acid synthase inhibitor TVB-2640 boasts a win in addressing the three key drivers of nonalcoholic steatohepatitis (NASH)—namely liver fat, fibrosis, and inflammation—in the phase II FASCINATE-1 trial presented during The Liver Meeting Digital Experience of the American Association for the Study of Liver Diseases (AASLD).